• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肯尼亚口服暴露前预防项目中妇女及其医疗保健提供者对即时检测评估替诺福韦依从性的可行性和建议。

Point-of-Care Test for Assessing Tenofovir Adherence: Feasibility and Recommendations from Women in an Oral PrEP Program in Kenya and Their Healthcare Providers.

机构信息

Centre for Clinical Research, Kenya Medical Research Institute, -PHRD, Thika Project, Nairobi, Kenya.

Health Behavior Health Education, School of Public Health, University of Michigan, Ann Arbor, MI, USA.

出版信息

AIDS Behav. 2021 Nov;25(11):3617-3629. doi: 10.1007/s10461-021-03255-3. Epub 2021 Apr 24.

DOI:10.1007/s10461-021-03255-3
PMID:33893877
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9271229/
Abstract

Oral pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention modality when taken as recommended. Women in sub-Saharan Africa may have adherence challenges that remain undisclosed to providers. Real-time measures that identify non-adherence can allow for immediate exploration of adherence challenges, counseling and interventions. We conducted a formative qualitative study in Kenya to explore oral PrEP experiences and reactions to a point-of-care urine test (UT) identifying recent (past 4 days) non-adherence to tenofovir-based PrEP among female PrEP users (25 in-depth interviews; 4 focus groups) and health care provider (10 key informant interviews). Findings indicate that use of the UT would be highly feasible in the context of regular PrEP care, largely acceptable to clients and providers, and could improve adherence. Clients emphasized the need for transparent client-centered strategies in delivering results. This formative study informs the development of tools to implement this point-of-care UT in future interventional studies and clinical settings.

摘要

口服暴露前预防(PrEP)在按建议服用时是一种非常有效的 HIV 预防方法。撒哈拉以南非洲的女性可能存在未向提供者透露的服药依从性挑战。实时识别不依从的措施可以允许立即探索服药依从性挑战、咨询和干预。我们在肯尼亚进行了一项形成性定性研究,以探索口服 PrEP 的经验以及对一种即时护理尿液检测(UT)的反应,该检测可识别最近(过去 4 天)基于替诺福韦的 PrEP 不依从情况,对象为女性 PrEP 用户(25 次深入访谈;4 次焦点小组)和医疗保健提供者(10 次关键知情人访谈)。研究结果表明,在定期 PrEP 护理的背景下,使用 UT 非常可行,对客户和提供者来说基本可以接受,并可以提高依从性。客户强调在提供结果时需要透明的以客户为中心的策略。这项形成性研究为未来干预性研究和临床环境中实施这种即时护理 UT 提供了工具开发的信息。

相似文献

1
Point-of-Care Test for Assessing Tenofovir Adherence: Feasibility and Recommendations from Women in an Oral PrEP Program in Kenya and Their Healthcare Providers.肯尼亚口服暴露前预防项目中妇女及其医疗保健提供者对即时检测评估替诺福韦依从性的可行性和建议。
AIDS Behav. 2021 Nov;25(11):3617-3629. doi: 10.1007/s10461-021-03255-3. Epub 2021 Apr 24.
2
Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.关于即时检验尿液替诺福韦以评估艾滋病病毒暴露前预防和抗逆转录病毒治疗依从性的效用和意义的观点:在美国客户和提供者中进行的探索性定性评估
AIDS Res Ther. 2020 Aug 6;17(1):50. doi: 10.1186/s12981-020-00308-w.
3
Urine tenofovir testing for real-time PrEP adherence feedback: a qualitative study involving transgender women in Uganda.尿液替诺福韦检测实时反馈事前预防用药依从性:乌干达跨性别女性参与的定性研究。
J Int AIDS Soc. 2024 May;27(5):e26255. doi: 10.1002/jia2.26255.
4
MPrEP+ study protocol: a prospective cohort study assessing the feasibility and acceptability of an HIV pre-exposure prophylaxis (PrEP) strategy for male clients of female sex workers in Kisumu, Kenya.MPrEP+ 研究方案:一项前瞻性队列研究,评估肯尼亚基苏木地区女性性工作者男性客户中使用 HIV 暴露前预防(PrEP)策略的可行性和可接受性。
BMJ Open. 2022 Nov 4;12(11):e064037. doi: 10.1136/bmjopen-2022-064037.
5
Impact of a point-of-care urine tenofovir assay on adherence to HIV pre-exposure prophylaxis among women in Kenya: a randomised pilot trial.肯尼亚基于即时检测点尿液替诺福韦检测的 HIV 暴露前预防用药依从性的影响:一项随机试点试验。
Lancet HIV. 2024 Aug;11(8):e522-e530. doi: 10.1016/S2352-3018(24)00125-5. Epub 2024 Jul 5.
6
Factors Associated with Usage of Oral-PrEP among Female Sex Workers in Nairobi, Kenya, Assessed by Self-Report and a Point-of-Care Urine Tenofovir Immunoassay.肯尼亚内罗毕的女性性工作者使用口服暴露前预防(PrEP)的相关因素评估:基于自我报告和即时尿液中替诺福韦免疫测定法。
AIDS Behav. 2024 Nov;28(11):3836-3849. doi: 10.1007/s10461-024-04455-3. Epub 2024 Aug 13.
7
The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.基于替诺福韦的暴露前预防在撒哈拉以南非洲高风险女性中预防 HIV 获得的效果:系统评价。
Pan Afr Med J. 2021 Mar 26;38:308. doi: 10.11604/pamj.2021.38.308.26014. eCollection 2021.
8
Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study.肯尼亚青少年女孩和年轻女性在坚持服药率低且药物未起到保护作用的情况下仍持续参加 PrEP 项目:一项前瞻性队列研究的结果。
PLoS Med. 2022 Sep 12;19(9):e1004097. doi: 10.1371/journal.pmed.1004097. eCollection 2022 Sep.
9
Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial.在肯尼亚进行的用于监测暴露前预防并提供反馈的替诺福韦实时尿液依从性检测试验(PUMA):一项试点随机对照试验方案
JMIR Res Protoc. 2020 Apr 2;9(4):e15029. doi: 10.2196/15029.
10
Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials.FEM-PrEP临床试验中自我报告和药丸计数依从性测量方法的准确性:对未来HIV预防试验的启示。
AIDS Behav. 2015 May;19(5):743-51. doi: 10.1007/s10461-014-0859-z.

引用本文的文献

1
Combining HIV prevention Options with Mental health service delivery for Adolescent girls and young women (CHOMA): results of a pilot hybrid effectiveness-implementation randomized trial in South Africa.为青春期女孩和年轻女性将艾滋病预防选项与心理健康服务相结合(CHOMA):南非一项试点混合效果-实施随机试验的结果
J Int AIDS Soc. 2025 Sep;28(9):e70037. doi: 10.1002/jia2.70037.
2
Cost and clinical flow of point-of-care urine tenofovir testing for treatment monitoring among people living with HIV initiating ART in South Africa.南非接受抗逆转录病毒治疗的艾滋病毒感染者中用于治疗监测的即时检测尿液替诺福韦的成本和临床流程
J Int AIDS Soc. 2025 Jul;28(7):e70004. doi: 10.1002/jia2.70004.
3
Urine tenofovir adherence testing: Perspectives of recently diagnosed South African adolescents and young adults with HIV accessing care via mobile HIV clinics.尿液替诺福韦依从性检测:近期确诊的南非青少年及青年艾滋病毒感染者通过流动艾滋病毒诊所接受治疗的观点。
PLoS One. 2025 Jan 31;20(1):e0318308. doi: 10.1371/journal.pone.0318308. eCollection 2025.
4
Acceptability and feasibility of a urine-based tenofovir adherence assay for monitoring and providing feedback on PrEP adherence in Kenya.一种基于尿液的替诺福韦依从性检测方法在肯尼亚用于监测和提供关于暴露前预防(PrEP)依从性反馈的可接受性和可行性。
AIDS Care. 2025 Feb;37(2):324-336. doi: 10.1080/09540121.2024.2444556. Epub 2024 Dec 28.
5
High recent PrEP adherence with point-of-care urine tenofovir testing and adherence counselling among young African women: results from the INSIGHT cohort.非洲年轻女性中近期通过即时检验尿替诺福韦检测及依从性咨询实现的高暴露前预防药物依从性:INSIGHT队列研究结果
J Int AIDS Soc. 2024 Dec;27(12):e26389. doi: 10.1002/jia2.26389.
6
The impact of adherence counseling incorporating a point of care urine tenofovir assay on virologic suppression among individuals failing tenofovir-lamivudine-dolutegravir: A pre-post intervention study.结合即时检验尿替诺福韦检测的依从性咨询对替诺福韦-拉米夫定-多替拉韦治疗失败个体病毒学抑制的影响:一项干预前后研究
Int J Infect Dis. 2025 Feb;151:107328. doi: 10.1016/j.ijid.2024.107328. Epub 2024 Dec 6.
7
Factors Associated with Usage of Oral-PrEP among Female Sex Workers in Nairobi, Kenya, Assessed by Self-Report and a Point-of-Care Urine Tenofovir Immunoassay.肯尼亚内罗毕的女性性工作者使用口服暴露前预防(PrEP)的相关因素评估:基于自我报告和即时尿液中替诺福韦免疫测定法。
AIDS Behav. 2024 Nov;28(11):3836-3849. doi: 10.1007/s10461-024-04455-3. Epub 2024 Aug 13.
8
Impact of a point-of-care urine tenofovir assay on adherence to HIV pre-exposure prophylaxis among women in Kenya: a randomised pilot trial.肯尼亚基于即时检测点尿液替诺福韦检测的 HIV 暴露前预防用药依从性的影响:一项随机试点试验。
Lancet HIV. 2024 Aug;11(8):e522-e530. doi: 10.1016/S2352-3018(24)00125-5. Epub 2024 Jul 5.
9
Point-of-care urine tenofovir test predicts future HIV preexposure prophylaxis discontinuation among young users.即时尿液替诺福韦检测可预测年轻使用者未来终止 HIV 暴露前预防用药的情况。
AIDS. 2024 Sep 1;38(11):1671-1676. doi: 10.1097/QAD.0000000000003962. Epub 2024 Jun 20.
10
Urine tenofovir testing for real-time PrEP adherence feedback: a qualitative study involving transgender women in Uganda.尿液替诺福韦检测实时反馈事前预防用药依从性:乌干达跨性别女性参与的定性研究。
J Int AIDS Soc. 2024 May;27(5):e26255. doi: 10.1002/jia2.26255.

本文引用的文献

1
Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings.开发并验证首个即时床旁检测方法,以在常规环境中实时、客观地监测艾滋病毒治疗和预防的依从性。
AIDS. 2020 Feb 1;34(2):255-260. doi: 10.1097/QAD.0000000000002395.
2
What Can Urine Tell Us About Medication Adherence?尿液能告诉我们关于药物依从性的哪些信息?
EClinicalMedicine. 2018 Sep 15;2-3:5-6. doi: 10.1016/j.eclinm.2018.09.003. eCollection 2018 Aug-Sep.
3
Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement.HIV 感染预防的暴露前预防:美国预防服务工作组推荐声明。
JAMA. 2019 Jun 11;321(22):2203-2213. doi: 10.1001/jama.2019.6390.
4
Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence.用于检测尿液中替诺福韦的免疫测定法的开发与验证:作为抗逆转录病毒治疗依从性的实时指标
EClinicalMedicine. 2018 Aug-Sep;2-3:22-28. doi: 10.1016/j.eclinm.2018.08.004. Epub 2018 Aug 31.
5
Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions.美国参与候选药物 PrEP 研究的女性的观点:坚持、可接受性和未来使用意向。
J Int AIDS Soc. 2019 Mar;22(3):e25247. doi: 10.1002/jia2.25247.
6
Challenges to PrEP use and perceptions of urine tenofovir adherence monitoring reported by individuals on PrEP.接受暴露前预防(PrEP)的个体报告的PrEP使用挑战及对尿替诺福韦依从性监测的看法。
AIDS Care. 2019 Oct;31(10):1203-1206. doi: 10.1080/09540121.2019.1587369. Epub 2019 Mar 1.
7
Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test.简报:用于监测 PrEP 和 ART 依从性的尿液替诺福韦免疫测定法的验证及建立即时检测的临界点。
J Acquir Immune Defic Syndr. 2019 May 1;81(1):72-77. doi: 10.1097/QAI.0000000000001971.
8
Global PrEP roll-out: recommendations for programmatic success.全球普及预防:项目成功的建议。
Lancet HIV. 2019 Feb;6(2):e137-e140. doi: 10.1016/S2352-3018(19)30002-5. Epub 2019 Jan 16.
9
Pharmacologic-Based Methods of Adherence Assessment in HIV Prevention.基于药理学的HIV预防依从性评估方法
Clin Pharmacol Ther. 2018 Dec;104(6):1056-1059. doi: 10.1002/cpt.1201. Epub 2018 Sep 4.
10
Deception in clinical trials and its impact on recruitment and adherence of study participants.临床试验中的欺骗行为及其对研究参与者招募和依从性的影响。
Contemp Clin Trials. 2018 Sep;72:146-157. doi: 10.1016/j.cct.2018.08.002. Epub 2018 Aug 21.